Company Profile
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Latest News
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.bayer.com |
| Audit Risk | 6 |
| Board Risk | 1 |
| Overall Risk | 1 |
| Market Cap | 45.86B |
| Forward P/E | 9.93 |
| Dividend Rate | 0.11 |
| Dividend Yield | 0.24% |
| Trailing Annual Div. Rate | 0.11 |
| Trailing Annual Div. Yield | 0.24% |
| Trailing EPS | -2.19 |
| Forward EPS | 4.7 |
| Book Value | 29.36 |
| Price-to-Book | 1.59 |
| Enterprise-to-Revenue | 1.72 |
| Enterprise-to-EBITDA | 7.64 |
| Ex-Dividend Date | 04/27/2026 |
| Earnings Date | 08/04/2026 |
| Earnings Call Date | 08/04/2026 |
| Earnings Average | 0.74 |
| Earnings Low | 0.62 |
| Earnings High | 0.81 |
| Revenue Average | 10.71B |
| Revenue Low | 10.50B |
| Revenue High | 10.79B |